It looks like it floats through the air, stabbing it with its dauntless silhouette. It drives with the confidence that not even a Chevy truck would. It roars like it's a wounded animal. It looks as if ...

During last night’s Gang of Threebroadcast, it’s true that I may or may not have said that the Pittsburgh Steelers are the “weaseliest” team in professional football. In fact, I’m pretty sure I did, ...

When Rian Johnson’s Knives Out first hit theaters, it wasn’t just a clever whodunit with an all-star ensemble cast. It was the birth of a new franchise, and an instantly iconic sleuth in Daniel ...

"Wake Up Dead Man: A Knives Out Mystery" is the latest installment in Rian Johnson's murder-mystery franchise. Daniel Craig returns as detective Benoit Blanc alongside a new ensemble cast including ...

The Memphis Flyer is Memphis’ alternative newsweekly, serving the metro Memphis area of nearly a million residents. The Flyer was started in 1989 by Contemporary Media, Inc., the locally owned ...

A whodunit is a bit like a basketball game: The last few minutes are all that really matter. Still, writer-director Rian Johnson managed to pump some life into a largely forgotten cinematic genre with ...

Texas has long bucked national interference, and Thanksgiving is no exception to Texas’ independent streak. In fact, Texas was the very last state in the nation to join the federal government in ...

With Rian Johnson’s killer murder mystery Wake Up Dead Man coming this holiday season, there’s no better time than now to take stock of the characters we’ve met over the last couple outings. From the ...

Billy Bob Thornton opened up about the challenges he faced as a southerner trying to make it in Hollywood during the early years of his career. While appearing alongside his "Landman" co-star Sam ...

Billy Bob Thornton still believes Hollywood looks down on people from the South. During an appearance on Joe Rogan's podcast, Thornton lit a cigarette and said there was a "prejudice" when he first ...

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.31 per share a year ago. These ...

Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP ...